Cardiovascular and microvascular outcomes with iGlarLixi versus iDegLira: A real-world, population-based cohort study.

Diabetes Obes Metab · 2022

Last updated 2026-05-28

Journal	Diabetes Obes Metab, 2022
Citations	4
Relative citation ratio	0.26
NIH percentile	16
Molecules	—
Conditions studied	Type 2 Diabetes, Cardiovascular Risk Reduction

Full record and abstract on PubMed 34676657 ↗